Skip to content

Single arm, open-label, multicenter clinical study for evaluation of the efficacy and safety of low-concentration sevoflurane for the treatment of autism spectrum disorder

Single arm, open-label, multicenter clinical study for evaluation of the efficacy and safety of low-concentration sevoflurane for the treatment of autism spectrum disorder

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027459
Enrollment
Unknown
Registered
2019-11-14
Start date
2019-11-15
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism spectrum disorder

Interventions

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Patients meeting the DSM-V diagnostic criteria for autism spectrum disorder 2. Male or female patients aged 3-18 years, right-handed; 3. Have the ability to complete all the tests; 4. The parents or legal guardians of the subjects have good reading and understanding skills, and can cooperate with the completion of the relevant assessment scale and follow-up. 5. Evidence of a subject (or a legal representative) signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study and are willing to participate in it.

Exclusion criteria

Exclusion criteria: 1. Other mental disorders other than autism spectrum disorder (such as epilepsy, schizophrenia, attention deficit hyperactivity disorder, stunted growth, cerebral ischemia and hypoxia, cephalitis, or craniocerebral injury; poisoning); 2. Patients with severe physical diseases or other systemic diseases (history of renal, hepatic, metabolic disorders, tumors, infections, organic diseases of the nervous system, endocrine, immunologic diseases); 3. Subjects with serum K+ or Mg2+ beyond the normal range; 4. A history of malignant syndrome or tardive dyskinesia history; 5. Monoamine oxidase antidepressants were administered prior to the study in 2 weeks; 6. Participation in other studies within the last 30 days before the current study begins and /or during study participation.

Design outcomes

Primary

MeasureTime frame
CARS;

Secondary

MeasureTime frame
ATEC;SRS;RBS-R;CSQ;TESS;

Countries

China

Contacts

Public ContactXingrong Song

Guangzhou Women and Children's Medical Center

sxjess@126.com+86 13922416303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026